Preliminary results from an ongoing phase 2a study of RX-3117, an oral nucleoside analogue to treat advanced urothelial cancer (aUC)
| Autor: | Hani M. Babiker, Scott T. Tagawa, Jacob Adashek, Christine B. Peterson, Julie Poore, Sumanta K. Pal, Raymond C. Wadlow, Joel Picus, Ely Benaim, Vincent Chung, Sumati Gupta |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Cancer Research Nucleoside analogue business.industry Small molecule 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Oncology 030220 oncology & carcinogenesis Cancer research medicine Urothelial cancer Uridine Cytidine Kinase business Nucleoside medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 36:4543-4543 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2018.36.15_suppl.4543 |
| Popis: | 4543Background: RX-3117 is an oral small molecule nucleoside analogue (cyclopentyl pyrimidyl nucleoside) that is activated by uridine cytidine kinase 2. RX-3117 shows efficacy in various xenograft ... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|